Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0819 biomarin hemophilia
BioCentury & Getty Images

Regulation

What FDA’s request for a new endpoint means for BioMarin’s hemophilia gene therapy

Collecting two-year data will set BioMarin back at least 15 months, but it still has a shot at getting its gene therapy to market first

Collecting two-year bleeding rates from all patients will set BioMarin back at least 15 months, but it still has a good shot at getting its gene therapy to market first.

Read the full 741 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE